{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:20:31Z","timestamp":1793910031367,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["Research\/Small\/5411\/2023-2024"],"award-info":[{"award-number":["Research\/Small\/5411\/2023-2024"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EM\/Dev\/SG\/170\/1232\/2023\/JJC"],"award-info":[{"award-number":["EM\/Dev\/SG\/170\/1232\/2023\/JJC"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007338","name":"All-India Institute of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.annonc.2025.12.015","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T23:56:48Z","timestamp":1766447808000},"page":"639-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial\u2014Pembrolizumab Low dose in Addition to NACT in TNBC)"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-8188","authenticated-orcid":false,"given":"A.","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0946-8518","authenticated-orcid":false,"given":"H.","family":"Bhaskarane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-7771","authenticated-orcid":false,"given":"G.","family":"Tansir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gogia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3402-9875","authenticated-orcid":false,"given":"K.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vishvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Rangarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-976X","authenticated-orcid":false,"given":"P.","family":"Tanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-7483","authenticated-orcid":false,"given":"C.P.","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5052-0499","authenticated-orcid":false,"given":"S.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6731-9249","authenticated-orcid":false,"given":"M.K.","family":"Divakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vasudeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3060-5794","authenticated-orcid":false,"given":"S.","family":"Agstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vuthaluru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3292-3611","authenticated-orcid":false,"given":"R.","family":"Parshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.K.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-7238","authenticated-orcid":false,"given":"S.","family":"Suhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3567-6292","authenticated-orcid":false,"given":"J.","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bhasker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.P.","family":"Haresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1934-8408","authenticated-orcid":false,"given":"A.","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.annonc.2025.12.015_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An overview of triple-negative breast cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch Gynecol Obstet"},{"issue":"9869","key":"10.1016\/j.annonc.2025.12.015_bib2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.annonc.2025.12.015_bib3","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2025.12.015_bib4","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.22.00503","volume":"40","author":"Korde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.12.015_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.annonc.2025.12.015_bib6","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.12.015_bib7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.annonc.2025.12.015_bib8","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.annonc.2025.12.015_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512478","article-title":"Advances in the management of early-stage triple-negative breast cancer","volume":"24","author":"Bhardwaj","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.annonc.2025.12.015_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/GO.23.00312","article-title":"Effectiveness of immune checkpoint inhibitors in various tumor types treated by low, per-weight, and conventional doses at a tertiary care center in Mumbai","author":"Patel","year":"2024","journal-title":"JCO Glob Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.12.015_bib11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/atm.2018.03.28","article-title":"Financial toxicity and implications for cancer care in the era of molecular and immune therapies","volume":"6","author":"Tran","year":"2018","journal-title":"Ann Transl Med"},{"issue":"19","key":"10.1016\/j.annonc.2025.12.015_bib12","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.annonc.2025.12.015_bib13","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.12.015_bib14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"Patil","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.12.015_bib15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000512000","article-title":"Low-dose nivolumab in renal cell carcinoma: a real-world experience","volume":"99","author":"Zhao","year":"2021","journal-title":"Oncology"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.12.015_bib16","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2024-208831","article-title":"Low-dose nivolumab plus AVD as front-line therapy for classical Hodgkin\u2019s lymphoma: preliminary results of a phase 2 trial","volume":"144","author":"Vega Mateos","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.annonc.2025.12.015_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.09.1157","article-title":"EP.11E.04: Low-dose nivolumab in advanced NSCLC; light at the end of the tunnel","volume":"19","author":"Alaga","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.12.015_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010065","article-title":"Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study","volume":"13","author":"Smeenk","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2025.12.015_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.960116","article-title":"Case report: pharmacokinetics of pembrolizumab in a patient with stage IV non-small cell lung cancer after a single 200 mg administration","volume":"12","author":"De Vries","year":"2023","journal-title":"Front Oncol"},{"issue":"17","key":"10.1016\/j.annonc.2025.12.015_bib20","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.12.015_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.12.015_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13063-025-08726-9","article-title":"A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC)","volume":"26","author":"Arora","year":"2025","journal-title":"Trials"},{"issue":"22","key":"10.1016\/j.annonc.2025.12.015_bib23","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.annonc.2025.12.015_bib24","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.annonc.2025.12.015_bib25","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1200\/JCO.23.00435","article-title":"Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP","volume":"41","author":"Litton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2025.12.015_bib26","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","volume":"25","author":"Hudis","year":"2007","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.annonc.2025.12.015_bib27","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.12.015_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","article-title":"Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer","volume":"178","author":"Cocks","year":"2023","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2025.12.015_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e43069","article-title":"Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: a systematic review and meta-analysis of real-world data","volume":"11","author":"Antonini","year":"2025","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.annonc.2025.12.015_bib30","first-page":"65","article-title":"Average relative dose intensity and the impact on design of clinical trials","volume":"14","author":"Hryniuk","year":"1987","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.12.015_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v069.i01","article-title":"Least-squares means: the R package lsmeans","volume":"69","author":"Lenth","year":"2016","journal-title":"J Stat Softw"},{"issue":"404","key":"10.1016\/j.annonc.2025.12.015_bib32","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1080\/01621459.1988.10478722","article-title":"A test of missing completely at random for multivariate data with missing values","volume":"83","author":"Little","year":"1988","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"10.1016\/j.annonc.2025.12.015_bib33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40271-022-00584-w","article-title":"Interpreting within-patient changes on the EORTC QLQ-C30 and EORTC QLQ-LC13","volume":"15","author":"Coon","year":"2022","journal-title":"Patient"},{"key":"10.1016\/j.annonc.2025.12.015_bib34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2025.12.015_bib35","article-title":"Does pathological complete remission after neoadjuvant chemotherapy translate to longer relapse-free survival in patients with triple-negative breast cancer in the Indian population?","volume":"39","author":"Sharma","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10257","key":"10.1016\/j.annonc.2025.12.015_bib36","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.annonc.2025.12.015_bib37","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/21645515.2016.1175694","article-title":"Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers","volume":"12","author":"Rajan","year":"2016","journal-title":"Hum Vaccines Immunother"},{"issue":"3","key":"10.1016\/j.annonc.2025.12.015_bib38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000276597","article-title":"Regional body composition of Indian women from a low-income group and its association with anthropometric indices and reproductive events","volume":"56","author":"Kulkarni","year":"2010","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.annonc.2025.12.015_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231210271","article-title":"What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?","volume":"15","author":"Kuah","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.annonc.2025.12.015_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.breast.2022.04.006","article-title":"Moment of truth-adding carboplatin to neoadjuvant\/adjuvant chemotherapy in triple negative breast cancer improves overall survival: an individual participant data and trial-level meta-analysis","volume":"64","author":"Pathak","year":"2022","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.annonc.2025.12.015_bib41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.12.015_bib42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.12.015_bib43","article-title":"Addition of carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer: a phase III randomized controlled trial","author":"Gupta","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 17","key":"10.1016\/j.annonc.2025.12.015_bib44","article-title":"NRG-BR003: a randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC","volume":"43","author":"Valero","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 9","key":"10.1016\/j.annonc.2025.12.015_bib45","article-title":"Abstract PO4-19-05: OptimICE-pCR: de-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103)","volume":"84","author":"Tolaney","year":"2024","journal-title":"Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425063355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425063355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:15:42Z","timestamp":1784704542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425063355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0923753425063355"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.12.015","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial\u2014Pembrolizumab Low dose in Addition to NACT in TNBC)","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}